Effect of Antigenic Heterogeneity on the Efficacy of Enhanced Delivery of Antibody-targeted Chemotherapy in a Human Lung Cancer Intracerebral Xenograft Model in Rats

@article{Neuwelt2003EffectOA,
  title={Effect of Antigenic Heterogeneity on the Efficacy of Enhanced Delivery of Antibody-targeted Chemotherapy in a Human Lung Cancer Intracerebral Xenograft Model in Rats},
  author={E. Neuwelt and L. Thrun and S. Walker-Rosenfeld and Andrew T. Cave and L. Muldoon},
  journal={Neurosurgery},
  year={2003},
  volume={53},
  pages={1406-1413}
}
  • E. Neuwelt, L. Thrun, +2 authors L. Muldoon
  • Published 2003
  • Medicine
  • Neurosurgery
  • OBJECTIVEThe SGN-15 monoclonal antibody-doxorubicin immunoconjugate is toxic to LewisY antigen-expressing cells and is effective against intracerebral tumors in nude rats when delivery is enhanced with osmotic disruption of the blood-brain barrier (BBB). We tested whether doxorubicin released locally in antigen-expressing cells would affect adjacent non-antigen-expressing cells in heterogeneously expressing intracerebral tumors. METHODSNude rats with intracerebral xenografts of human small cell… CONTINUE READING
    10 Citations
    BR96–DOX Immunoconjugate Targeting of Chemotherapy in Brain Tumor Models
    • 37
    Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.
    • 290
    • PDF
    Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma
    • 40
    Cell killing by antibody-drug conjugates.
    • 166
    Biotechnology, the brain and the future.
    • S. Greenfield
    • Computer Science, Medicine
    • Trends in biotechnology
    • 2005
    • 16
    • PDF

    References

    SHOWING 1-10 OF 44 REFERENCES
    Differential permeability of a human brain tumor xenograft in the nude rat: impact of tumor size and method of administration on optimizing delivery of biologically diverse agents.
    • 38
    Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.
    • 139
    Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.
    • 39
    • PDF
    Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity.
    • 73
    • PDF
    Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.
    • 229